Sept 18 (Reuters) - Bellus Health Inc BLU.TO
* Bellus Health's BLU-5937 significantly reduces cough without taste disturbance in two preclinical models
* Bellus Health Inc - BLU-5937's reduction in cough frequency comparable to leading P2X3 antagonist, Gefapixant
* Bellus - in rat taste model, BLU-5937 didnt inhibit taste; but consistent with trial data presented by Merck (NYSE:MRK), Gefapixant did significantly impact taste